TELA Bio, Inc. Common Stock
Symbol: TELA (NASDAQ)
1.71
▼ (-7.84%) -0.145
Company Description:
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Key Stats
- Today's Open: $1.83
- Today's High: $1.914
- Today's Low: $1.677
- Today's Volume: 166.03K
- Yesterday Close: $1.85
- Yesterday High: $1.93
- Yesterday Low: $1.81
- Yesterday Volume: 92.18K
- Last Min Volume: 0
- Last Min High: $1.705
- Last Min Low: $1.705
- Last Min VWAP: $0
Company Profile
- Name: TELA Bio, Inc. Common Stock
- Website: https://www.telabio.com
- Listed Date: 2019-11-08
- Location: MALVERN, PA
- Market Status: Active
- CIK Number: 0001561921
- SIC Code: 3841
- SIC description: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
- Market Cap: $73.57M
- Round Lot: 100
- Outstanding Shares: 39.55M
- Asset Type: CS
RECENT FILINGS FOR TELA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-06-02 | 4 | View |
| 2025-06-02 | 8-K | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 8-K | View |
| 2025-05-30 | SCHEDULE 13G/A | View |
| 2025-05-30 | SCHEDULE 13G | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-08 | 8-K | View |
| 2025-05-08 | SCHEDULE 13G/A | View |
| 2025-05-07 | SCHEDULE 13G/A | View |
| 2025-04-17 | ARS | View |
| 2025-04-17 | DEFA14A | View |
| 2025-04-17 | DEF 14A | View |
| 2025-04-07 | PRE 14A | View |
| 2025-04-02 | 4 | View |
Latest News on TELA